Non-Viral Vector Development Platforms
The vector part of the non-viral vector introduction system generally refers to plasmid DNA, or it can also be a vector-free nucleic acid, such as antisense oligonucleotides, ribozyme, siRNA, etc. Our company focuses on common non-viral vectors and their potential future applications, helping our customers to design and develop more novel, highly efficient, and less toxic multifunctional non-viral vectors to further accelerate the progress of gene therapy for rare diseases.
Non-Viral Vectors as Delivery System
Synthetic non-viral vectors offer more modification possibilities to obtain the desired properties of gene delivery systems, including biocompatibility and efficient nucleic acid delivery with high functional activity. Substances that can often be used to construct non-viral vector delivery systems include lipids, polysaccharides, polypeptides or proteins, polyhistidine or polylysine, multivalent cationic compounds, steroids, etc.
Fig.1 The enhancement approaches of viral vector and non-viral vector. (Sandbrink, J. B., et al., 2023)
Advantages of Non-Viral Vectors
In recent years, non-viral vectors have received increasing attention due to their unique advantages.
- Non-viral vectors are easy to produce at scale for commercial synthesis and are storage stable.
- Compared with viral vectors, the toxicity, inflammatory response and off-target effects of the vector are improved.
- The combination of nanotechnology and nucleic acid-based molecules shows great potential in the field of drug delivery.
Our Services
With many years of experience, our company provides comprehensive non-viral vector development, as well as non-viral vector characterization services, to provide you with customized solutions for rare disease research projects, including but not limited to:
Help customers develop a wide range of liposome formulations for DNA, messenger RNA (mRNA), siRNA, and antisense oligonucleotide delivery in gene therapy, including but not limited to:
Design nanoparticle vectors according to specific sizes, structures and geometries to provide you with new gene delivery systems that are safe, effective and affordable.
- Polymer-based Vectors Development
Provide polyethyleneimine (PEI), poly(L-lysine) (PLL), poly[2-(dimethyamino)ethyl methacrylate] (PDMAEM), poly(amidoamine) (PAMAM), and chitosan (CS) to help customers design efficient and safe non-viral vectors for gene therapy, including but not limited to:
In addition to the above services, other optional services include:
Project Workflow
Our company offers comprehensive services and technical support for every stage of rare disease research. Our extensive experience in providing non-viral vector development allows us to provide you with customized services as well as comprehensive assistance that can help you move from rare disease therapy development to therapy commercialization. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
Reference
- Sandbrink, J. B., et al. "Insidious Insights: Implications of viral vector engineering for pathogen enhancement." Gene Therapy 30.5 (2023): 407-410.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
